Akili
The study did not find find a significant difference in depression symptoms between the intervention and control group.
Also: Fitbit may be able to tell you how much you snore, and psychedelic-focused startup Mind Cure Health joins the DTx Alliance.
The company plans to use the new funds to expand its therapeutics beyond ADHD.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
It's been quite a year for digital, from Akili's de novo clearance to the downfall of 'digital pill' maker Proteus. MobiHealthNews takes a look back at the highlights.
The long-awaited decision is the first regulatory authorization for Akili, and the first game-based therapeutic that the FDA has greenlit for any condition.
In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.
The large, multi-site investigation described clear improvement in objective symptoms of pediatric attention deficit, but was a bit muddier when describing subjective measures and long-term efficacy.
Topline data released today by the digital therapeutics company also suggest that its FDA approval-pending treatment continued to deliver benefits with continued use.
Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.